PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
1234.83%
Other expenses growth above 1.5x CRVO's 100.00%. Michael Burry would check for concerning trends.
115.67%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
115.67%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
719.71%
Interest expense change of 719.71% while CRVO maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
115.67%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.51%
Tax expense change of 133.51% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
-133.51%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-132.80%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-132.80%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.